Achromatopsia is a rare stationary retinal disorder that primarily affects the cone photoreceptors. Individuals with achromatopsia present with photophobia, nystagmus, reduced visual acuity (VA), and color blindness. Multiple genes responsible for achromatopsia have been identified (e.g. cyclic nucleotide-gated channel subunit alpha 3 [CNGA3] and activating transcription factor 6). Studies have assessed the role of gene therapy in achromatopsia. Therefore, for treatment and prevention, the identification of phenotypes and genotypes is crucial. Here, we described the clinical manifestations and genetic mutations associated with achromatopsia in patients from Saudi Arabia.
This case series study included 15 patients with clinical presentations, suggestive of achromatopsia, who underwent ophthalmological and systemic evaluations. Patients with typical achromatopsia phenotype underwent genetic evaluation using whole-exome testing.
All patients had nystagmus ( = 15) and 93.3% had photophobia ( = 14). In addition, all patients ( = 15) had poor VA. Hyperopia with astigmatism was observed in 93.3% ( = 14) and complete color blindness in 93.3% of the patients ( = 14). In the context of family history, both parents of all patients ( = 15) were genetic carriers, with a high consanguinity rate (82%, = 9 families). Electroretinography showed cone dysfunction with normal rods in 66.7% ( = 10) and both cone-rod dysfunction in 33.3% ( = 5) patients. Regarding the genotypic features, 93% of patients had variants in ( = 14) categorized as pathogenic Class 1 (86.7%, = 13). Further, 66.7% ( = 10) of patients also harbored the c.661C>T DNA variant. Further, the patients were homozygous for these mutations. Three other variants were also identified: c.1768G>A (13.3%, = 2), c.830G>A (6.6%, = 1), and c. 822G >T (6.6%, = 1).
Consanguinity and belonging to the same tribe are major risk factors for disease inheritance. The most common genotype was with the c.661C>T DNA variant. We recommend raising awareness among families and providing genetic counseling for this highly debilitating disease.
Copyright: © 2023 Saudi Journal of Ophthalmology.
